Clinical Trial: Canakinumab for Treatment of Adult Onset Still's Disease
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Canakinumab for Treatment of Adult Onset Still's Disease to Achieve Reduction of Arthritic Manifestation
Brief Summary: Interleukin-1 antagonists such as canakinumab have been used for the treatment of AOSD and have had a marked influence on the activity of the disease, including joint mobility. Results from controlled clinical studies are not, however, currently available.
Detailed Summary:
Sponsor: Charite University, Berlin, Germany
Current Primary Outcome: Efficacy of canakinumab with a clinically-significant reduction in disease activity [ Time Frame: 12 weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Charite University, Berlin, Germany
Dates:
Date Received: July 29, 2014
Date Started: June 2012
Date Completion: August 2017
Last Updated: July 25, 2016
Last Verified: July 2016